The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2, open-label study of oral S241656 (BDTX-4933) as monotherapy and in combination with other anti-cancer therapies in patients with KRAS, BRAF and other selected RAS/MAPK mutation positive malignancies.
 
Ajay Prakash
No Relationships to Disclose
 
Michael Offin
Honoraria - OncLive
Consulting or Advisory Role - American Society for Radiation Oncology; Jazz Pharmaceuticals; Novartis; Pfizer; PharmaMar; SERVIER; Targeted Oncology; Vivace Therapeutics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
(OPTIONAL) Uncompensated Relationships - Mesothelioma Applied Research Foundation
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Pfizer; Regeneron; Vertex
Consulting or Advisory Role - AADi; Enlaza Therapeutics; Whitehawk Therapeutics
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Arcus Biosciences (Inst); Artios (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Boundless Bio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Circle Pharma (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Day One Biopharmaceuticals (Inst); Debiopharm Group (Inst); Deciphera (Inst); EvolveImmune Therapeutics (Inst); Exelixis (Inst); Exscientia (Inst); FoRx Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Halda Therapeutics (Inst); Helsinn Therapeutics (Inst); Iambic Therapeutics (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Ipsen (Inst); Johnson & Johnson/Janssen (Inst); Johnson & Johnson/Janssen (Inst); KLUS Pharma (Inst); Kumquat Biosciences (Inst); Macrogenics (Inst); Mbrace Therapeutics (Inst); MediLink Therapeutics (Inst); Menarini Group (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mitsubishi Tanabe Pharma (Inst); Moderna Therapeutics (Inst); Monte Rosa Therapeutics (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Olema Pharmaceuticals (Inst); Opna Bio (Inst); Pfizer (Inst); Pliant (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Third Arc Bio (Inst); Treeline Biosciences (Inst); VelaVigo Bio (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Sylvia Lee
Research Funding - Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead Company (Inst); PACT Pharma (Inst); Seagen (Inst); Tmunity Therapeutics, Inc. (Inst)
 
Maria Baggstrom
Research Funding - Alliance for Clinical Trials in Oncology (Inst); Black Diamon Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Mythic Therapeutics (Inst); Nuvalent, Inc. (Inst)
 
Agathe Lepissier
Employment - Servier/Pfizer
 
Vanessa Seif
Employment - SERVIER
 
Zhaowei Hua
Employment - SERVIER
 
Kabir Mody
Employment - SERVIER
Stock and Other Ownership Interests - CytoDyn; Moderna Therapeutics
Research Funding - Agios (Inst); ARIAD (Inst); ArQule (Inst); AstraZeneca (Inst); Basilea (Inst); FibroGen (Inst); Gritstone Bio (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); TRACON Pharma (Inst); Turnstone Bio (Inst); Vyriad (Inst)
 
Jia Luo
Honoraria - Medscape; Physicans' Education Resource; Targeted Oncology
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca
Research Funding - Amgen; Black Diamond Therapeutics; Genentech; Kronos Bio; Novartis; Revolution Medicines
Patents, Royalties, Other Intellectual Property - A patent filed by Memorial Sloan Kettering Cancer Center related to multimodal features to predict response to immunotherapy (PCT/US2023/021178). (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Jiaxin Niu
Consulting or Advisory Role - AstraZeneca; Bristol Mers Squibb; Daiichi Sankyo; G1 Therapeutics; Johnson & Johnson; Mirati Therapeutics; Pfizer; Sanofi; Takeda